An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay
Viruses · 2023
DOI: 10.3390/v15091855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Jing Zou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Neutralization Tests, Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health, Sealy & Smith Foundation, Robert J Kleberg Jr and Helen C Kleberg Foundation.
Abstract (Originalsprache)
A reliable and efficient serological test is crucial for monitoring neutralizing antibodies against SARS-CoV-2 and its variants of concern (VOCs). Here, we present an integrated research–clinical platform for a live SARS-CoV-2 neutralization assay, utilizing highly attenuated SARS-CoV-2 (Δ3678_WA1-spike). This strain contains mutations in viral transcription regulation sequences and deletion in the open-reading-frames 3, 6, 7, and 8, allowing for safe handling in biosafety level 2 (BSL-2) laboratories. Building on this backbone, we constructed a genetically stable reporter virus (mGFP Δ3678_WA1-spike) by incorporating a modified green fluorescent protein sequence (mGFP). We also constructed mGFP Δ3678_BA.5-spike and mGFP Δ3678_XBB.1.5-spike by substituting the WA1 spike with variants BA.5 and XBB.1.5 spike, respectively. All three viruses exhibit robust fluorescent signals in infected cells and neutralization titers in an optimized fluorescence reduction neutralization assay that highly correlates with a conventional plaque reduction assay. Furthermore, we established that a streamlined robot-aided Bench-to-Clinics COVID-19 Neutralization Test workflow demonstrated remarkably sensitive, specific, reproducible, and accurate characteristics, allowing the assessment of neutralization titers against SARS-CoV-2 variants within 24 h after sample receiving. Overall, our innovative approach provides a valuable avenue for large-scale testing of clinical samples against SARS-CoV-2 and VOCs at BSL-2, supporting pandemic preparedness and response strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA.
- Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
- Sealy Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX 77555, USA.
ORCID-Profile: Chaitanya Kurhade, David Beaver, Pei-Yong Shi, Ping Ren
Förderung
- National Institute of Health
- Sealy & Smith Foundation
- Robert J Kleberg Jr and Helen C Kleberg Foundation
- John S. Dunn Foundation
- Amon G. Carter Foundation
- Gilson Longenbaugh Foundation
- Summerfield Robert Foundation
- NIAID
Zitieren
APA
Zou, J., Kurhade, C., Chang, H. C., Hu, Y., Meza, J. A., Beaver, D., Trinh, K., Omlid, J., Elghetany, B., Desai, R., McCaffrey, P., Garcia, J. D., Shi, P. Y., Ren, P., & Xie, X. (2023). An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay. Viruses. https://doi.org/10.3390/v15091855
Vancouver
Zou J, Kurhade C, Chang HC, Hu Y, Meza JA, Beaver D, et al. An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay. Viruses. 2023. doi:10.3390/v15091855
BibTeX
@article{Zou2023,
author = {Zou, Jing and Kurhade, Chaitanya and Chang, Hope C and Hu, Yanping and Meza, Jose A and Beaver, David and Trinh, Ky and Omlid, Joseph and Elghetany, Bassem and Desai, Ragini and McCaffrey, Peter and Garcia, Juan D and Shi, Pei-Yong and Ren, Ping and Xie, Xuping},
title = {An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15091855}
}
EUVIMED